Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial.

MLA

Tarride, Jean-Eric, et al. “Hospitalization Costs with Degludec versus Glargine U100 for Patients with Type 2 Diabetes at High Cardiovascular Risk: Canadian Costs Applied to SAEs from a Randomized Outcomes Trial.” Journal of Medical Economics, vol. 24, no. 1, Jan. 2021, pp. 1318–26. EBSCOhost, https://doi.org/10.1080/13696998.2021.2003804.

APA

Tarride, J.-E., Husain, M., Andersen, A., Gundgaard, J., Luckevich, M., Mark, T., Wagner, L., & Pieber, T. R. (2021). Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial. Journal of Medical Economics, 24(1), 1318–1326. https://doi.org/10.1080/13696998.2021.2003804

Chicago

Tarride, Jean-Eric, Mansoor Husain, Andreas Andersen, Jens Gundgaard, Maria Luckevich, Thomas Mark, Lily Wagner, and Thomas R Pieber. 2021. “Hospitalization Costs with Degludec versus Glargine U100 for Patients with Type 2 Diabetes at High Cardiovascular Risk: Canadian Costs Applied to SAEs from a Randomized Outcomes Trial.” Journal of Medical Economics 24 (1): 1318–26. doi:10.1080/13696998.2021.2003804.